Nicola Crosetto Group
Our group will use state-of-the-art molecular biology tools and technologies to develop single-cell and spatially resolved methods to quantify clinically relevant biomarkers and measure cellular drug responses. We will translate our innovations to challenging problems in medical oncology, including measuring biomarker heterogeneity in primary versus metastatic lesions, assessing the clinical impact of genetic diversity across different tumor areas, predicting drug responses based on biomarker dynamics profiling, and quantifying genomic instability during chemo- and radiation therapy.
We welcome people from different backgrounds – including medicine, engineering, and biotechnology – willing to engage in clinically driven technology innovation and with a strong motivation to improve the management of cancer patients by making oncology a more quantitative discipline.
For more detailed information about our lab visit bienkocrosettolabs.org.